NCT07147413 Digital Health Platform Blood Pressure Management Study
| NCT ID | NCT07147413 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Condition | Hypertension Prevention and Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,726 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,726 participants in total. It began in 2025-09-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study evaluated the effectiveness of an AI health education assistant compared to case manager support in hypertension management. Key outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), compliance with health behaviors, 722 goal achievement (monitoring, measurements, lifestyle improvements), and Technology Acceptance Model (TAM) metrics, including perceived usefulness (PU), perceived ease of use (PEU), and behavioral intention (BI). This study aims to examine whether the AI assistant group will achieve greater reductions in systolic and diastolic blood pressure compared to the case manager group. Additionally, it will evaluate whether the AI assistant group will demonstrate higher engagement in 722 goals and greater perceived ease of use. The results of this study are expected to provide further evidence supporting the potential of AI-driven interventions.
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1. Aged 18 to 75 years at the time of enrollment 2. Able and willing to provide informed consent 3. Able to operate a mobile phone and interact with the digital platform 4. Willing to participate in home blood pressure monitoring Exclusion Criteria: Participants will be excluded if they meet any of the following criteria: 1. Systolic BP consistently \<120 mmHg and diastolic BP \<70 mmHg, based on baseline home monitoring (considered low BP not targeted in this study) 2. Pregnant or planning to become pregnant during the study period 3. Unable to operate a smartphone or digital device independently 4. Cognitive impairment or language barrier that prevents understanding of study procedures or informed consent 5. Severe comorbidities that may interfere with study participation or outcomes (e.g., advanced heart failure, end-stage renal disease) 6. Current participation in another interventional clinical study that could conflict with this protocol 7. Unwillingness to follow home blood pressure monitoring protocol or adhere to follow-up schedule
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07147413 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hypertension Prevention and Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147413 currently recruiting?
Yes, NCT07147413 is actively recruiting participants. Contact the research team at hmcheng@vghtpe.gov.tw for enrollment information.
Where is the NCT07147413 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07147413 clinical trial?
NCT07147413 is sponsored by Taipei Veterans General Hospital, Taiwan. The trial plans to enroll 1,726 participants.